NYSE:CBT - Cabot Stock Price, News & Analysis

Cabot trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBT."

Cabot announced a quarterly dividend on Friday, July 12th. Shareholders of record on Friday, August 30th will be paid a dividend of $0.35 per share on Friday, September 13th. This represents a $1.40 annualized dividend and a yield of 3.61%. The ex-dividend date is Thursday, August 29th. View Cabot's Dividend History.

Cabot declared that its board has authorized a share repurchase program on Monday, July 16th 2018, which allows the company to repurchase $400,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 10.3% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's leadership believes its shares are undervalued.

Cabot Corp (NYSE:CBT) announced its earnings results on Monday, August, 5th. The specialty chemicals company reported $1.00 earnings per share for the quarter, hitting analysts' consensus estimates of $1.00. The specialty chemicals company earned $845 million during the quarter, compared to analysts' expectations of $858.86 million. Cabot had a return on equity of 18.60% and a net margin of 6.49%. The company's quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.06 earnings per share. View Cabot's Earnings History.

Cabot is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Cabot.

4 equities research analysts have issued 1 year target prices for Cabot's shares. Their predictions range from $40.00 to $76.00. On average, they expect Cabot's share price to reach $50.50 in the next year. This suggests a possible upside of 30.1% from the stock's current price. View Analyst Price Targets for Cabot.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabot in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cabot.

Headlines about CBT stock have been trending negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cabot earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave headlines about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Cabot.

Cabot saw a decline in short interest during the month of July. As of July 31st, there was short interest totalling 788,300 shares, a decline of 7.6% from the June 30th total of 853,500 shares. Based on an average daily trading volume, of 365,400 shares, the short-interest ratio is presently 2.2 days. Approximately 1.4% of the company's stock are sold short. View Cabot's Current Options Chain.

Some companies that are related to Cabot include Versum Materials (VSM), Platform Specialty Products (PAH), WD-40 (WDFC), Element Solutions (ESI), Orion Engineered Carbons (OEC), Advanced Emissions Solutions (ADES), Flotek Industries (FTK), Pure Bioscience (PURE), HighCom Global Security (HCGS), GlyEco (GLYE), Artemis Therapeutics (ATMS) and Ener-Core (ENCR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabot investors own include Broadcom (AVGO), Energy Transfer LP Unit (ET), JPMorgan Chase & Co. (JPM), Oracle (ORCL), Adobe (ADBE), Gilead Sciences (GILD), AT&T (T), Wells Fargo & Co (WFC), Cisco Systems (CSCO) and Micron Technology (MU).

Cabot's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.20%), Vanguard Group Inc. (8.93%), LSV Asset Management (4.78%), Bank of New York Mellon Corp (4.63%), Earnest Partners LLC (4.07%) and Bank of America Corp DE (2.05%). Company insiders that own Cabot stock include Brian A Berube, Gottberg Friedrich Von, Hobart Kalkstein, James Patrick Kelly, Michael M Morrow, Nicholas S Cross, Patrick M Prevost and Sean D Keohane. View Institutional Ownership Trends for Cabot.

CBT stock was sold by a variety of institutional investors in the last quarter, including Quest Capital Management Inc. ADV, BlackRock Inc., Russell Investments Group Ltd., Grantham Mayo Van Otterloo & Co. LLC, Vanguard Group Inc., AQR Capital Management LLC, Los Angeles Capital Management & Equity Research Inc. and D. E. Shaw & Co. Inc.. Company insiders that have sold Cabot company stock in the last year include Nicholas S Cross and Patrick M Prevost. View Insider Buying and Selling for Cabot.

CBT stock was purchased by a variety of institutional investors in the last quarter, including Earnest Partners LLC, Nuveen Asset Management LLC, Bank of America Corp DE, Royal Bank of Canada, Deprince Race & Zollo Inc., Wells Fargo & Company MN, WBI Investments Inc. and Icon Advisers Inc. Co.. View Insider Buying and Selling for Cabot.

Shares of CBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBT stock can currently be purchased for approximately $38.82.

Cabot has a market capitalization of $2.24 billion and generates $3.24 billion in revenue each year. The specialty chemicals company earns $-113,000,000.00 in net income (profit) each year or $4.03 on an earnings per share basis. Cabot employs 4,600 workers across the globe.View Additional Information About Cabot.

The official website for Cabot is http://www.cabot-corp.com/.

Cabot's mailing address is TWO SEAPORT LANE SUITE 1300, BOSTON MA, 02210. The specialty chemicals company can be reached via phone at 617-345-0100 or via email at [email protected]